POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, will report its financial results for the first half of 2019 on August 26, 2019.
August 22, 2019
· 2 min read